Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20747616 | 0.92 | LMNA (0.38) | LMNASMPD1MAPTMEN1KMT2A | |
| SCHEMBL20747631 | 0.91 | LMNA (0.37) | LMNASMPD1MAPTMEN1KMT2A | |
| SCHEMBL20747771 | 0.87 | SLC15A1 (0.34) | LMNAMAPTSLC15A1FAAHFDPS | |
| SCHEMBL20747726 | 0.84 | LMNA (0.39) | LMNASMPD1MAPTMEN1KMT2A | |
| SCHEMBL20747662 | 0.84 | LMNA (0.39) | LMNASMPD1MAPTMEN1KMT2A | |
| SCHEMBL20747664 | 0.84 | GRIN2D (0.36) | LMNA | |
| SCHEMBL20747689 | 0.83 | LMNA (0.36) | LMNASMPD1MAPTSLC15A1MEN1 | |
| SCHEMBL20747624 | 0.82 | DPP4 (0.33) | LMNAMAPTSLC15A1 | |
| SCHEMBL22951491 | 0.82 | MAPT (0.43) | LMNAMAPTMEN1KMT2AATM | |
| SCHEMBL20747623 | 0.80 | LMNA (0.45) | LMNASMPD1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208045-B2 | Aza-pyridone compounds and uses thereof | ALIOS BIOPHARMA, INC. (US) | 2019-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208045-B2 | Aza-pyridone compounds and uses thereof | PNPO, ITPA, PDXK | LMNA 2972/4885SMPD1 2070/4885MAPT 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.